SenesTech, Inc. (NASDAQ: SNES) reported Q3 EPS of ($0.09), in-line with the analyst estimate of ($0.09).

"We have always known that ContraPest was an effective solution in lab and controlled settings in reducing the population of rats, however this is an opportunity to showcase and validate the effectiveness in a larger, less controlled setting. This data will be quite helpful to our team's marketing efforts within the municipal market vertical. I thank Washington D.C. for their commitment to deploy ContraPest, and now expand it on a city-wide basis to win the 'war on rats,'" commented Ken Siegel, SenesTech's CEO.

For earnings history and earnings-related data on SenesTech, Inc. (SNES) click here.